New isogenic cell models created by CRISPR genome editing for drug discovery


Time: 12:00 PM Eastern Standard Time


The recent development of the CRISPR/Cas9 system provides a revolutionary gene-editing technology for basic research in biology and for development of targeted cancer therapies. In addition to enabling the identification of novel drug targets through functional screening, CRISPR/Cas9 facilitates the creation of disease models for drug discovery and development.

In this webinar, ATCC experts will address how ATCC utilized this advanced technology to create novel human cell models that contain disease-relevant point mutations and gene rearrangements. In addition, we will introduce a new type of BRAF inhibitor-resistant cell line that was created by using CRISPR/Cas9 to insert the NRAS Q61K mutation. These human isogenic lines provide useful disease models for the identification and validation of new therapeutics.

Key Points:

  • CRISPR/Cas9 gene editing technology is a powerful tool for drug discovery
  • Gene editing technology can be used to create disease-relevant cell models for screening new anti-cancer drug targets
  • CRISPR/Cas9 is a useful tool for creating new types of drug-resistant cell models


Fang Tian, Ph.D.

Fang Tian, Ph.D.,
Lead Scientist, ATCC Cell Systems

Dr. Fang Tian, Lead Scientist, head of the Translational Cell Biology Group for ATCC Cell Systems, has extensive experience in cell biology and molecular biology. She oversees human, animal cell lines and hybridomas, and product development in the Cell Biology General Collection at ATCC. Dr. Tian was a research fellow in Massachusetts General Hospital, Harvard Medical School. She conducted postdoctoral research at the Hillman Cancer Institute of UPMC.

Lysa-Anne Volpe, M.S.

Lysa-Anne Volpe, M.S.,
Senior Biologist, ATCC Cell Systems

Lysa-Anne Volpe, M.S., is a Senior Biologist with the Translation Cell Biology Group at ATCC. She possesses over 8 years of experience in cell molecular biology and genetics. Ms. Volpe has used the CRISPR/Cas9 system for in vitro mammalian genome engineering for several years. She studied Molecular Biology and Genetics at Colorado State University and advanced in vitro and in vivo model systems at the University of Colorado Denver Anschutz Medical Campus.